1 / 38

A History of the Science and Politics of ibogaine

A History of the Science and Politics of ibogaine. Howard S. Lotsof Dora Weiner Foundation Staten Island, NY @ 6th National HRC Conference Oakland, CA November 2006. Ibogaine Found in a West African plant Tabernanthe iboga. Iboga alkaloids are concentrated in the bark of the root.

muriel
Download Presentation

A History of the Science and Politics of ibogaine

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A History of the Science and Politics of ibogaine Howard S. Lotsof Dora Weiner Foundation Staten Island, NY @ 6th National HRC Conference Oakland, CA November 2006

  2. Ibogaine Found in a West African plant Tabernanthe iboga

  3. Iboga alkaloids are concentrated in the bark of the root

  4. Usable forms include scraped or ground root bark

  5. Total Alkaloid extract Courtesy Sara Glatt

  6. Purified Chemical Courtesy Jason Callan President and Founder Ethnogarden Botanical www.ethnogarden.com

  7. Proposed as an approved regulated drug

  8. Physical Characteristics of ibogaineSource Merck Index Chemical formula C20H26N2O Mol. Wt. 310.42 Melting Point 152-153° Practically insoluble in water. Soluble in ethanol, ether, chloroform Molecular structure

  9. The first attempt at drug development of ibogaine was by the Dora Weiner Foundation in 1983. In 1986, a for-profit corporation, NDA International, Inc. was established and subsequently raised 4 million towards the approval of ibogaine, initiating research and patent development. 1991, National Institute on Drug Abuse ibogaine research project. 1993, FDA approval for University of Miami clinical study. Regulatory and Scientific Development

  10. Rapid method for interrupting the narcotic addiction syndrome, US 4,499,096 (1985) Rapid method for interrupting the cocaine and amphetamine abuse syndrome US 4,587,243 (1986) Rapid method for attenuating the alcohol dependency syndrome, US 4,957,523 (1989) Rapid method for interrupting or attenuating the nicotine/tobacco dependency syndrome, US 5,026,697 (1991) Rapid method for interrupting or attenuating poly-drug dependency syndromes, US 5, 124,994 (1992) Ibogaine Patents

  11. First scientific publication of ibogaine antiaddictive effects

  12. Additional research supports Dr. Dzoljic’s findings. Dr. Stanley D. Glick at Albany Medical College begins the publication of what will be dozens of research papers

  13. Ibogaine effects on cocaine(Cappendijk & Dzoljic)

  14. Ibogaine effects on alcohol(Rezvani et al. 1995)

  15. Opioid withdrawal in human subjects

  16. Second generation ibogaine-like drug, metabolite noribogaine is identified

  17. Another second generation ibogaine-like drug, 18-methoxycoronaridine,diminished morphine withdrawal

  18. 18-methoxycoronaridineeffects on alcohol

  19. 18-methoxycoronaridineeffects on methamphetamine and nicotine

  20. Clinical use 18-methoxycoronaridine: No Noribogaine: No Ibogaine: YesApproximately 4,000 patients have been treated with ibogaine. Ten fatalities have been reported within 72 hours of administration in ibogaine treated patients.

  21. Ibogaine science continues to grow providing 100s of peer reviewed papers

  22. National Institute on Drug Abuse (NIDA) funds 85% of drug addiction research worldwide

  23. NIDA was petitioned to perform ibogaine research 1984 - 1990, first by the Dora Weiner Foundation and from 1986 on by NDA International, Inc., a company established to make ibogaine available as an approved medication. In 1991, NIDA formed its Medications Development Division (MDD) and accepted a Product Profile Review (PPR) from NDA International that resulted in NIDA starting their ibogaine research program. NIDA Initially Rejects Ibogaine Research.

  24. Ibogaine Activist Advocacy Organizations PlayRole in Ibogaine Development • International Coalition for Addict Self-Help (ICASH) 1989 • Dutch Addict Self-Help (DASH) 1990 • Cures-Not Wars (ibogaine and other issues) 1994 • Ibogaine Underground 2004

  25. ICASH logo Used to attract attention of government officials and media

  26. Nico Adriaans was one of the founders of both the Rotterdam Junkies Union and Dutch Addict Self-Help (DASH). DASH was an ibogaine self-help organization that petitioned the Dutch government and organized drug users to demand ibogaine availability. DASH provided ibogaine at no cost to heroin users.

  27. ICASH Organizing in the US

  28. Cures-Not-Wars placed pressure on NIDA to support Ibogaine research through protests

  29. Mindvox internet ibogaine list(user advocacy continues) “We all got to help each other best we can. No one else gives a shit ‘bout us hippy freak junkies? ” anon. To join send an email to ibogaine-subscribe@mindvox.com

  30. “FM- … We feel that continuing the focus offshore, outside the US, has not served a majority of people inside the US. Like many other grassroots movements, which facilitated change, treatments, sessions, need to be done where they belong, in all major US cities, as cost effectively as possible. “http://www.drugwar.com/ibonyc.shtm Ibogaine underground appears 2004

  31. Ibogaine represents both harm reduction and demand reduction DEA desk officer in the Netherlands asks how the Dutch are allowing a demand reduction drug like ibogaine to be researched in the Netherlands? Ibogaine proponents view the drug as significant harm reduction tool and basis for political action.

  32. Stigma A mark of disgrace associated with a particular circumstance, quality or person: for instance the stigma of chemical dependence.

  33. Ibogaine has the ability to remove the stigmatized condition, transforming the patient to a state often described as a preaddictive. The transformation of a stigmatized person into one who is not stigmatized will have significant affects on the individual and the society, allowing a greater contribution to self and society. Ibogaine Effects on Stigma

  34. Industry deems ibogaine not to be profitable. (not a maintenance drug) 2. The molecule is found in nature and cannot be owned. 3. Stigmatized patient population with liability higher than general population due to a greater mortality rate. 4. Government, industry and academia chose to place their interest to treat narcotic dependence in the development of opiate drugs with which they are familiar. 5. Ibogaine represents a new scientific paradigm to the understanding of addiction. • Lack of prioritization of pharmacotherapies. Why ibogaine is not available

  35. Failed to adequately respondto make ibogaine available • The medical community • The pharmaceutical industry • Government

  36. Paths to ibogaine availability Pharmaceutical company or government agency prepared to finance regulatory development. Supplies of pharmaceutical grade ibogaine. Grassroots constituency demanding availability of ibogaine. Political advocacy movement to pressure government and industry into action. A scientific community supporting ibogaine research.

  37. Why ibogaine should be available Ibogaine significantly reduces withdrawal Interrupts drug craving Returning patients to a preaddictive state Eliminates stigma Returns free choice

  38. Its in your hands now!Activism and advocacy must be renewed

More Related